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Editorial on the Research Topic
Manufacturing, Formulation and Delivery Issues for Phage Therapy to Become A Reality
There is resurgent interest in the use of bacteriophages (phages) as medicinal biological
therapeutics. This is driven partly by increases in antibiotic resistance in pathogenic bacteria as well
as an increasing awareness of the importance of the commensal microbiomes. Indeed, regarding
their high species specificity, phages fully respond to the Ehrlich’s magic bullet concept (Heynick,
2009), and represent therefore an attractive alternative or adjunct treatment to conventional broad-
spectrum antibiotics. Previously concluded phage therapy clinical trials including the Nestlé trial to
treat Escherichia coli associated diarrhea in children (Sarker et al., 2016) and the PhagoBurn effort
by Pherecydes Pharma to treat Pseudomonas aeruginosa infections in burn wounds (Jault et al.,
2018) however, have highlighted major manufacturing, formulation, and delivery challenges that
need to be urgently addressed.
Future personalized medicine approaches may necessitate distributed, near-patient
manufacturing of phages. The need to scale-up production to multiple manufacturing sites
or nearer to the patient within healthcare settings may require novel manufacturing approaches
that are compliant from a regulatory point of view. Flexible modern scalable production
approaches following the standards of current Good Manufacturing Practices (cGMP) are needed
to supply clinicians with stable phage products of suitable quality, safety, and efficacy. Moreover,
personalized medicine implies development of new designs for future randomized clinical trials,
which remain mandatory to demonstrate the considerable potential of phage therapy (Bretaudeau
et al.).
Increasing manufacturing robustness and standardizing phage production processes under the
guidelines of cGMP to guarantee patient safety is the focus of the mini-review by Mutti and
Corsini. The authors advocate using a quality-by-design approach to guide phage product and
process development at each step. The team responsible for manufacturing phage cocktail batches
for the Phagoburn trial share their experiences in a mini-review on cGMP compliance for phage
therapy medicinal products (Bretaudeau et al.). Overall, the need for consistent manufacturing
processes with a rigorous Quality Assurance (QA) system in place is deemed essential and
experience in the field of vaccines for human and veterinary use may be a useful future guide.
An important manufacturing consideration relies on the selection of suitable bacterial production
strains that preferably should be devoid of virulence determinants and of potential contaminant
temperate phages (Philipson et al., 2018). All authors agree that optimization of the upstream
(USP) and downstream purification processes (DSP) is crucial to ensure consistent yields and
quality. Lastly, consideration of the final formulation and early initiation of stability studies are
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deemed essential. All-in-one characterization of a multivalent
phage cocktail as a medicinal drug product is highlighted as
challenging and requiring future development of suitable
analytical methods. Development of on-line (real-time
measurement within the process) and at-line (sample taken
away and measurements taken off-line) metrology techniques
for precise enumeration and characterization of the biophysical
properties of phage drug products as part of QC testing needs
further research.
The purity of phage medicinal drug products is not only an
important safety consideration but impacts on phage stability
as well. Hietala et al. demonstrate the utility of ultrafiltration
for phage concentration as well as buffer exchange for the
efficient removal of small bacterial protein toxins. A general
low-cost scalable method for removing bacterial endotoxin
remains a challenge although encouraging results are presented
for a commercial affinity column or using anion exchange
chromatography. Accordingly, the paper highlights that the
DSP purification stack needs to not only meet relevant
purity threshold criteria but also allow high product recovery,
which could be challenging and an area for future process
development research.
Dry powder formulation of phages is an important Research
Topic regarding drug administration through inhalation for
patients suffering from lung infection (Malik, 2020). It is also
as an appealing way to improve phage storage stability, e.g., in
countries where a reliable cold supply chain is a problem (Carrigy
et al., 2019; Vinner et al., 2019a). Atmospheric spray freeze drying
(ASFD) of phages formulated using trehalose and mannitol as
excipients is explored in the original research paper by Ly et al.
as an alternative process in preserving phage biopharmaceutical
products. ASFD has advantages over conventional lyophilisation
methods, such as tray freeze drying, in terms of better heat and
mass transfer rates, resulting in considerably faster processing
times. There is also better control over the microstructure of the
resulting spray dried powders, which can ease re-solubilization
prior to administration (Malik et al., 2017).
Developing new approaches for oral administration and
improving bioavailability of phages for human therapeutic
and animal biocontrol targeting gastrointestinal applications is
another important research area (Vinner et al., 2019b). Protecting
phages from stomach acidity and increasing the residence time
of phages through interaction of encapsulated phages with the
intestinalmucosa has previously been shown (Colom et al., 2015).
The original research paper by Otero et al. in this special issue
explores the use of fluorescently labeled phages encapsulated in
liposomes and employs a non-invasive imaging system to track
the biodistribution and residence time of the phages in vivo in a
mouse model.
In summary, this special issue brings together a number
of original research articles and mini-reviews that address
important bacteriophage manufacturing (including cGMP
manufacture) and formulation challenges to ensure future
medicinal phage drug products meet quality, safety and
efficacy criterion.
AUTHOR CONTRIBUTIONS
DM and GR were joint co-editors of this special issue and
co-wrote the editorial. Both authors contributed equally to the
article and approved the submitted version.
ACKNOWLEDGMENTS
The editors would like to acknowledge and thank the
researchers who contributed manuscripts for this special
issue. We would also like to thank the reviewers who
kindly gave their time to carefully and critically read
the manuscripts and make constructive suggestions for
their improvement.
REFERENCES
Carrigy, N. B., Liang, L., Wang, H., Kariuki, S., Nagel, T. E., Connerton,
I. F., et al. (2019). Trileucine and pullulan improve anti-campylobacter
bacteriophage stability in engineered spray-dried microparticles.
Ann. Biomed. Eng. 48, 1169–1180. doi: 10.1007/s10439-019-02
435-6
Colom, J., Cano-Sarabia, M., Otero, J., Cortés, P., Maspoch, D., and Llagostera,
M. (2015). Liposome-encapsulated bacteriophages for enhanced oral phage
therapy against Salmonella spp. Appl. Environ. Microbiol. 81, 4841–4849.
doi: 10.1128/AEM.00812-15
Heynick, F. (2009). The original ‘magic bullet’ is 100 years old - extra. Br. J.
Psychiatry 195, 456. doi: 10.1192/bjp.195.5.456
Jault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y.-A., Resch, G., et al.
(2018). Efficacy and tolerability of a cocktail of bacteriophages to treat burn
wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised,
controlled, double-blind phase 1/2 trial. Lancet Infect. Dis. 19, 35–45.
doi: 10.1016/S1473-3099(18)30482-1
Malik, D. J. (2020). Bacteriophage encapsulation using spray drying for
phage therapy. Curr. Issues Mol. Biol. 40, 303–316. doi: 10.21775/cimb.
040.303
Malik, D. J., Sokolov, I. J., Vinner, G. K., Mancuso, F., Cinquerrui, S.,
Vladisavljevic, G. T., et al. (2017). Formulation, stabilisation and encapsulation
of bacteriophage for phage therapy. Adv. Colloid Interface Sci. 249, 100–133.
doi: 10.1016/j.cis.2017.05.014
Philipson, C. W., Voegtly, L. J., Lueder, M. R., Long, K. A., Rice,
G. K., Frey, K. G., et al. (2018). Characterizing phage genomes
for therapeutic applications. Viruses 10:188. doi: 10.3390/v100
40188
Sarker, S. A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton,
F., et al. (2016). Oral phage therapy of acute bacterial diarrhea
with two coliphage preparations: a randomized trial in children
from Bangladesh. EBiomedicine 4, 124–137. doi: 10.1016/j.ebiom.
2015.12.023
Vinner, G. K., Rezaie-Yazdi, Z., Leppanen, M., Stapley, A. G. F., Leaper,
M. C., and Malik, D. J. (2019a). Microencapsulation of Salmonella-
specific bacteriophage Felix O1 using spray-drying in a pH-responsive
formulation and direct compression tableting of powders into a
solid oral dosage form. Pharmaceuticals 12, 1–14. doi: 10.3390/ph120
10043
Vinner, G. K., Richards, K., Leppanen, M., Sagona, A. P., and Malik, D. J.
(2019b). Microencapsulation of enteric bacteriophages in a pH-Responsive
Frontiers in Microbiology | www.frontiersin.org 2 October 2020 | Volume 11 | Article 584137
Malik and Resch Editorial: Phage Manufacturing, Formulation and Delivery
solid oral dosage formulation using a scalable membrane emulsification
process. Pharmaceutics 11:475. doi: 10.3390/pharmaceutics11090475
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Malik and Resch. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 3 October 2020 | Volume 11 | Article 584137
